Small Cell Lung Cancer

Excited to see the latest @charlesrudin lab paper published in @ScienceTM: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity https://t.co/sKHYNaave7 (@AlvaroQuintanal)

That's true if the system was all based on CEA, that in fact commonly it's not. One can be more prone to uptake low-value higher cost/QALY when the tailored pop is tiny (late line SCLC), because budget impact eventually matters on how you break down recources. (@darioT_)

Looking to learn about the latest developments in understanding #SCLC biology, relevant subtypes & clinical trials? Watch this new #MedEd video produced with @LUNGevity and featuring @teekayowo, @LealTiciana, & Dr. Carl Gay https://t.co/9hoGbxKPOa #ASCO23 (@PeerView)

Bazı kanserler çok hızlı yayılıyor. SCLC çok agresif. Hızlı şekilde extended evreye geçiliyor. Hastaların çoğu belirti farkettiginde son aşamada oluyor. Ayrıca covid kanser metastazını artıyor muhtemelen. Hocamız daha doğru bilgi verir. (@stocktr2022)

Agree - for AML, SCLC, pancreas, GBM, other aggressive diseases, no need for a surrogate endpoint when using the harder-to-fudge OS is reasonable (@Eddie_Cliff)

También publicamos la segunda parte de las guías mexicanas para el tratamiento del cáncer de pulmón de células pequeñas #SCLC #GAMO #SMEO #MJO @incanMX @SMEOMX @Tu_IMSS @ISSSTE_mx @HemOncINCMNSZ https://t.co/vvUOr7gRls (@EnriqueSoto8)

Fantastic review and updates on SCLC. Congratulations to all co-authors ! @LaurenByersMD @HeekeSimon @fred_hirsch (@BZhangMD)

Disseminated small cell lung cancer is an extreme example. It's not as if second-line NSCLC has such a long time line that we can't get a timely answer to OS. We have erred way too much on side of surrogate endpoints giving us false signals. And those who say PFS alone should… https://t.co/NlkQ0HgocY (@JackWestMD)

It has been an honor to coordinate with Dr. @charocampelo these excellent SCLC experts to publish the new @_SEOM and @gecp_org guidelines for SCLC. New data and strategies. @Hospital_FJD @UAM_Madrid @DocenciaFJD @AEACaP @OncoAlert #LCSM #SCLC (@ManuelDomine)

Inova Lung Cancer Researcher Leads Study Offering New Hope for Small Cell Lung Cancer Patients - Inova Newsroom ⁦@InovaSchar⁩ ⁦@InovaHealth⁩ ⁦⁦⁦@LaurenByersMD⁩ ⁦@ReckampK⁩ ⁦@RamSubraMD⁩ ⁦@triparnasen⁩ https://t.co/B8bIrtmmUL (@NaglaAKarimMD)

Coming soon - my conversation with Dr. @christine_lovly and Dr. Smruthy Sivakumar about this brilliant analysis on #SCLC. Stay tuned to @LUNGevity for future air date! (@acmoorephd)

Excited to share our analysis of 3,600 “real world” cases of Small Cell Lung Cancer (SCLC) – @christine_lovly #cancer #brainmetastases #lungcancer #mutations #realworld #tumors #oncology #oncodaily https://t.co/ihtdnq3tie (@oncodaily)

Watch #SCLC experts @teekayowo, @LealTiciana, & Carl M. Gay, MD, PhD, to receive nuanced guidance on how to make the most of current therapies and updates on emerging treatment strategies in this #MedEd video produced with @LUNGevity: https://t.co/9hoGbxKPOa #MedTwitter #ASCO23 (@PeerView)

El profesor ⁦@edgardo_ny⁩ covers gaps in knowledge and new studies for locally advanced lung cancer and SCLC at Best of ⁦@ASCO⁩ Miami - safety of chemoIO w radiation and IO/IO - RT—> targeted therapies -best approaches for treating pts w poos PS #lcsm ⁦ (@Latinamd)

Have seen at least 3 cases of long covid that turned out to be 1. Small cell lung cancer 2. RA ILD 3. Acute eosinophilic pneumonia. All felt like they had covid, but the test came negative. But still got diagnosed with it. (@Drhtaha)

Dr. @edgardo_ny provides an update on #SCLC at the Miami Best of ASCO, outlining the current chemo-immunotherapy standard and the hope for personalized therapies. S1929 with Dr. @NaglaAKarimMD was an important proof of concept study from #ASCO23 (@StephenVLiu)

#OpenAccess article and commentary by @BrunaPellini and @aadel_chaudhuri https://t.co/MgtW5zAXRY https://t.co/JC2dUvgqaA @CCR_AACR #SCLC #LCSM @hopkinskimmel @VUMC_Cancer @MoffittNews @WashU_ctDNA (@ValsamoA)

TODAY 13:00 - 14:15 CEST @etop_ibcsg Live Webinar: Highlights of AACR and ASCO 2023 #RadOnc topics: - LS SCLC - Sulcus superior tumor - Tumor treating Fields Join @peters_solange and many more ! https://t.co/OTGFPVEW1h (@Mat_Guc)

🎥@LealTiciana of @WinshipAtEmory discusses personalized treatment for #SCLC based on subsets: SCLC-A, SCLC-P, SCLC-I, and triple-negative. Exciting prospects for chemoimmunotherapy in SCLC-I: ➡️https://t.co/Q3jjoDodVi⬅️ #ASCO23 @ASCO #LungCancer #LCSM (@VJOncology)

They are not small but SCLC 🤔 (@Histopatolomon)

Researchers with the @VanderbiltU #NCICSBC Center, including @quarantalab, @ceelox4, @AWeaverLab, & @christine_lovly, are quantitatively assessing the plasticity and dynamics of cancer cell phenotypes in small cell #lungcancer (#SCLC). https://t.co/xXDBrOqV0e #LCSM (@NCIsysbio)

This SCLC session is too much fun... despite what he implies in this intro slide @teekayowo delivers an excellent review of lubrinectedin vs topotecan in the elderly. "I don't have SCLC, but if I did, topotecan would not be my first choice!" - Dr. Paul Bunn #DAVAHawaiiLung https://t.co/mK0i1Ni28E (@KE_Gallaway)

New targets in SCLC including DLL3 nicely summarized by @teekayowo @DAVAOnc (@PatelOncology)

Starting Now: Relapsed SCLC: Current and Emerging Agents. Moderated by: Lauren Byers. @LaurenByersMD #DAVAHawaiiLung (@DAVAOnc)

No conference on lung cancer is complete without a good pun from the one & only @DrSteveMartin 😂 Excellent summary of the activity of lurbinectedin in the 2L setting for patients with SCLC #DAVAHawaiiLung #lcsm (@esinghimd)

"So when you're snorkeling with all the fish and wondering why they don't get SCLC, maybe it's because of the sea squirt!" - @DrSteveMartin delivers a witty and Hawaii-appropriate lecture on the antitumor activity of lurbinectedin in 2L SCLC #DAVAHawaiiLung https://t.co/mK0i1Ni28E (@KE_Gallaway)

✨ So great to hear from @BZhangMD, our newest thoracic faculty member @MDAndersonNews, as she presents exciting updates on personalizing SCLC therapy for our patients. #DAVAHawaiiLung #lcsm (@esinghimd)

Outstanding talk by Dr @GavittWoodard from @YaleSurgery on the anticipated rise in surgery for small-cell. “Sharpen your knives!” @DAVAOnc @WomenInThoracic @WomenSurgeons Followed by stellar presentation from @MDAndersonNews’s @LaurenByersMD on emerging opportunities in SCLC. (@maraantonoff)

Starting Now: Biology and Management of Newly Diagnosed SCLC. Moderated by: Taofeek Owonikoko @teekayowo #DAVAHawaiiLung (@DAVAOnc)

DLL3/CD3 BiTE抗体; ASCO23 NotchリガンドのDLL3はSCLCやNECの細胞表面発現しています. BI764532は, DLL3/CD3に結合し, T細胞を活性化させるBiTE抗体. 本試験は, 進行小細胞肺癌や大細胞神経内分泌癌に対するBI 764532の有効性と安全性を検証した用量漸増試験. #ASCO23 (@ZhgNHUVKOZq0IYN)

2 weeks ago- a magical cruise on the Nile with my brilliant colleagues. A memorable evening of #friendship, #collaboration & #strategies to control #lungcancer. @NaglaAKarimMD @karenkellymd @maiofegypt @BrainTumorDoc @RamSubraMD #SCLC #WomenInSTEM #womeninthoraciconcology (@triparnasen)

tl;dr - molecular similarities b/w SCBC & well-defined subtypes of SCLC may aid in clinical management & future research efforts Kudos team 👏 @WC_Houston @djmcconkey @JCensits @MaxKates @SHPatelMD1 @Andres_Matoso @JHBladderCancer @brady_urology @HopkinsMedicine (@urogabe)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 discuss whether adding a PARP inhibitor is beneficial to patients with small cell lung cancer (SCLC). https://t.co/1OD3uPajYQ For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Looking forward to working with my friend @ChristianRolfo on this exciting project funded by @NFCR using #liquidbiopsy to understand and track #therapy #resistance in #SCLC. @IcahnMountSinai @TischCancer #LCSM #lungcancer #CTC (@triparnasen)

.@ChristianRolfo and @triparnasen received a grant from @NFCR for research on #SCLC. They will use #NGS to evaluate mutations and identify mechanisms of resistance to therapies. @MSHSThoracicOnc @IcahnMountSinai (@TischCancer)

Congrats @ChristianRolfo and @triparnasen! Elucidating the mechanisms of resistance to currently approved therapies is essential for moving forward to personalized medicine in SCLC! (@Al3ssandroRusso)

SWOG S1929; ASCO23 SLFN11陽性のES-SCLCに対する維持治療として, アテゾリズマブとPARP阻害薬talazoparibの併用療法の有効性をみたPII試験です. PFSでは有意差がついていますが, OSは有意差がありませんでした. #ASCO23　＃小細胞肺癌 (@ZhgNHUVKOZq0IYN)

…& it was a wrap!! Thank you @SyrigosKostas @fred_hirsch @DrRoyHerbstYale for organizing such an amazing meeting. Two days of #science, #discussions, #collaboration, #learning #advocacy & meeting friends & colleagues. #lungcancer #LCSM #SCLC @olakhorshid Pasi Jane, Raj Veluswamy (@triparnasen)

🎯 Will DLL3-targeting agents “notch” up renewed hope for patients with metastatic SCLC? ✍️ Excellent review of emerging data in this space by @charlesrudin @MSKCancerCenter et al. @OncoAlert @LungCancerRx #lcsm (@esinghimd)

#ILCN An inspiring lecture on novel strategies to improve dismal outcomes in #SCLC by the Unique @charlesrudin ➡️ restoring antigen presentation capacity(MHCI) ➡️ enabling T-cell engagement ( BiTES) ➡️Epigenetic regulation of inflamed phenotype @fred_hirsch @Oncoalert #some (@g_mountzios)

Thank you @g_mountzios for your kind talk. It is a great pleasure to be here and interact with my colleagues at the #ILCN meeting. #lungcancer #SCLC #lineageplasticity @SyrigosKostas @DrRoyHerbstYale @fred_hirsch (@triparnasen)

I totally agree with this retrospective analysis @UKT_RadOnc @uktuebingen Even in the era of immunotherapy there is room for thoracic radiotherapy in ES-SCLC! I think it is very important to control the mediastinal disease avoiding it becomes symptomatic, thus improving QoL. (@FabArcidiacono8)